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The  purpose  of the  study  was  to explore  the  feasibility  of  a  protocol  for the isolation  and  molecular
characterization  of single  circulating  tumor  cells  (CTCs)  from  cancer  patients  using  a single-cell  next
generation  sequencing  (NGS)  approach.
To reach  this  goal  we  used  as  a model  an  artiﬁcial  sample  obtained  by spiking  a breast  cancer  cell line
(MDA-MB-231)  into  the  blood  of  a healthy  donor.
Tumor  cells  were  enriched  and  enumerated  by CellSearch® and  subsequently  isolated  by  DEPArrayTM to
obtain  single  or pooled  pure samples  to  be submitted  to the analysis  of the  mutational  status  of  multiple
genes  involved  in  cancer.
Upon  whole  genome  ampliﬁcation,  samples  were  analysed  by  NGS  on the Ion  Torrent  PGMTM system
(Life  Technologies)  using  the  Ion  AmpliSeqTM Cancer  Hotspot  Panel  v2  (Life Technologies),  designed  to
investigate  genomic  “hot  spot”  regions  of  50 oncogenes  and  tumor  suppressor  genes.
We  successfully  sequenced  ﬁve  single  cells,  a pool  of 5 cells  and DNA  from  a cellular pellet  of  the  same
cell  line  with  a  mean  depth  of  the  sequencing  reaction  ranging  from  1581  to 3479  reads.
We  found  27 sequence  variants  in 18  genes,  15  of which  already  reported  in the COSMIC  or  dbSNP
databases.  We  conﬁrmed  the  presence  of  two  somatic  mutations,  in  the  BRAF  and  TP53  gene,  which  had
been  already  reported  for this  cells  line,  but  also  found  new  mutations  and  single  nucleotide  polymor-
phisms.  Three  variants  were  common  to  all the analysed  samples,  while  18  were  present  only in  a single
cell  suggesting  a high  heterogeneity  within  the same  cell  line.
This paper  presents  an  optimized  workﬂow  for the  molecular  characterization  of  multiple  genes  in
single  cells  by NGS.  The  described  pipeline  can  be  easily  transferred  to the  study  of single  CTCs  from
oncologic  patients.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC. Introduction
The molecular analysis of solid tumors is of great impact in the
eld of oncology research notwithstanding some unsolved chal-
enging aspects in both sample selection and technical approaches.
olid tumors are in fact a heterogeneous mixture of tumor and nor-
al  cells differentially contributing to the ﬁnal results of molecular
iology tests on nucleic acids. As a result molecular signatures rep-
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liniche Università Degli Studi di Firenze Viale Pieraccini, 6 50139 Firenze, Italy.
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214-7535/© 2015 The Authors. Published by Elsevier GmbH. This is an open access artic
.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
resent an average value masking the individual signals deriving
from each single cancer cell [1]. The analysis of somatic mutations
at the single-cell level can evidence whether one or more variants
detected in the bulk tissue are simultaneously present in the same
cell or if, on the contrary, derive from different cell clones.
Next-generation sequencing (NGS) has become a major tool for
nucleic acid analysis and promises to disclose the basis of dis-
eases, opening perspectives for increased personalized therapies
and screening [2]. NGS has been so far applied to nucleic acids deriv-
ing from a high number of cells providing global information on
the average state of the entire population of cells [1]. By combining
whole genome ampliﬁcation (WGA) with NGS, it is now possible to
achieve individual cancer cell sequencing [3].
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Single-cell sequencing has the potential to address some
mportant questions in oncology such as understanding tumor het-
rogeneity, reconstructing cell lineages and deﬁning the genome of
are tumor cell populations [3–5].
In addition, single-cell technologies will contribute to elucidate
are cell events such as scarce cancer cells in clinical samples and
he dissemination of circulating tumor cells (CTCs) in the blood of
ancer patients [1,6]. Since CTCs reﬂect the heterogeneity of pri-
ary or metastatic tumors, their analysis at the single-cell level
epresent a real time liquid biopsy of the disease giving an insight
n cancer progression, helping in the choice of target therapies or
n the prediction of the efﬁcacy of chemotherapeutic agents [1]
nd thus representing a key tool in the development of precision
edicine.
Another aspect that can be considered as an application of
ingle-cell sequencing is the analysis of cell lines derived from
umors that are commonly used as models in cancer research. This
pproach can be successfully adopted to identify those cell lines
hat more closely resemble the characteristics of the tumor under
tudy [7]. Even if at a much lower extent than tissues, the cell line
opulation usually considered as composed of identical cellular ele-
ents can hide a heterogeneity that could be disclosed only by
ingle-cell analysis.
The MDA-MB-231 is an adherent human breast cancer cell line
f epithelial origin, which is highly aggressive, invasive and poorly
ifferentiated. MDA-MB-231 cells display a mesenchymal-like phe-
otype thus representing a good model for metastatic breast cancer
8].
In the present study we investigated the mutational status of
ultiple genes on an artiﬁcial sample obtained by spiking the MDA-
B-231 cell line into the blood of a healthy donor. The tumor
ells were immunomagnetically isolated by CellSearch® (Veridex,
SA), sorted by a dielectrophoretic system (DEPArrayTM, Silicon
iosystems, Italy) and then submitted to WGA  and targeted deep
equencing. We used this model with the aim to demonstrate the
easibility of a workﬂow for the isolation and molecular character-
zation of single circulating tumor cells from cancer patients using
 single-cell NGS approach.
. Methods
.1. Cell culture and spiking experiments
Experiments were conducted on the MDA-MB-231 human
reast cancer cell line. MDA-MB-231 cells were obtained from
i.V.A.L. Toscana (Laboratory for Drug Validation and Antibody pro-
uction, University of Florence) and maintained in DMEM (Lonza,
asel, Switzerland) + 10% FBS (PAA Laboratories, Austria) at 37 ◦C in
% CO2. Cells were detached from plastic surface by Accutase (PAA
aboratories) to better preserve membrane antigens. MDA-MB-231
ells (n = 500) were spiked in blood samples from a healthy vol-
nteer collected in CellSave® tubes (Veridex LLC, Raritan, NJ) and
rocessed as described below. The remaining cells from the same
ulture were centrifuged and the resulting cell pellet was submitted
o DNA extraction by QIAamp DNA Mini Kit (Qiagen, Germany).
.2. Cell enrichment and enumeration
Cell enrichment and enumeration was performed by the
ellSearch® System. 7.5 mL  of whole blood were processed using
he CellSearchTM Epithelial Cell kit (Veridex LLC), which selects
pCAM positive cells using ferroﬂuids particles coated with EpCAM
ntibody. Cells were stained with the nuclear dye 4′,6′-diamino-2-
henylindole (DAPI), anti-cytokeratin 8, 18 and 19-phycoerythrin
PE) labelled antibodies, and CD45 antibody labelled with allophy- and Quantiﬁcation 5 (2015) 23–29
cocyanin (APC). After enrichment, isolated and stained cells were
resuspended in the MagNest Device (Veridex LLC), labelled cells
were analyzed in the CellTracks® Analyzer II (Veridex LLC) and cells
identiﬁed and enumerated according to the criteria speciﬁed by the
manufacturer’s instructions.
2.3. Single cell sorting
Following CellSearch® enrichment the sample was recovered
from the Veridex cartridge and loaded into the DEPArrayTM A300K
chip (Silicon Biosystems) according to the manufacturer’s instruc-
tions. The chip is a single-use, microﬂuidic cartridge containing
an array of individually controllable electrodes, each one with
embedded sensors. Chip scanning was performed by an auto-
mated ﬂuorescence microscope to generate an image gallery, with
cells selected according to their morphology (round shape, round
nucleus within the cytoplasm) and staining pattern deriving from
that of the CellSearch® system: DAPI positive, PE positive (CK8,
CK18, CK19 positive cells), APC negative (CD45 negative cells).
After tumor cell identiﬁcation, single cells or groups of few cells
were recovered into 200 l tubes.
2.4. Whole genome ampliﬁcation
Single cells or pools of cells were submitted to WGA  using the
Ampli1TM WGA  kit (Silicon Biosystems) according to the manu-
facturer’s instructions, in order to obtain a sample suitable for
sequencing analysis. The procedure is based on a ligation-mediated
PCR following a site speciﬁc DNA digestion by MseI enzyme. The
kit has no needs for precipitation steps avoiding DNA loss and pro-
vides a library of fragments of about 0.2-2 kb representing the entire
genome. The kit uses a mixture of Taq polymerase with a proofread-
ing enzyme, Pwo polymerase, that has been reported to have error
rates more than 10 times lower than the error rate observed with
Taq polymerase [9].
2.5. WGA  quality control
The quality of the output product of the WGA  reaction was
assessed by the Ampli1TM QC kit (Silicon Biosystems) according to
the manufacturer’s instructions. The kit is a PCR-based assay which
implies the ampliﬁcation of two distinct regions of the human
genome to produce two amplicons (A and B) of 373 and 167 bp
respectively. PCR products A and B were analyzed by capillary
electrophoresis on the Agilent 2100 Bionalyzer. The presence of
both ampliﬁcation products indicates a successful WGA  and con-
sequently the suitability of the sample for downstream analysis.
2.6. Next generation sequencing
Sequencing analysis was performed on the Ion Torrent PGMTM
system (Life Technologies). We  ampliﬁed the samples using the Ion
AmpliSeqTM Cancer Hotspot Panel v2 (Life Technologies) designed
to target 207 amplicons covering mutations from 50 oncogenes and
tumor suppressor genes. DNA quantiﬁcation was assessed using
the Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA).
Ten nanograms of DNA were used to prepare barcoded libraries
using the Ion AmpliSeqTM Library kit 2.0 and Ion XpressTM bar-
code adapters (Life Technologies). The libraries were puriﬁed with
Agentcourt AMPure XP (Beckman Coulter) and quantiﬁed with the
Ion Library Quantitation Kit (Life Technologies) on the StepOne Plus
system (Applied Biosystem).
Template preparation was performed with the Ion OneTouchTM
2 System and Ion One Touch ES. Finally sequencing was  performed
on PGM using Ion PGMTM Sequencing 200 kit v2 (Life Technologies)
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Table  1
Classiﬁcation of genes of the AmpliSeqTM Cancer Hotspot Panel v2 on the basis of
the presence of the MseI restriction site in one or more amplicons.
31 Unaffected genes 17 Partially affected genes 2 Totally affected genes
ABL1 APC NPM1
AKT1 ATM JAK2
ALK CDH1
BRAF EGFR
CDKN2A ERBB4
CSF1R FBXW7
CTNNB1 FGFR2
ERBB2 KDR
EZH2 KIT
FGFR1 KRAS
FGFR3 MET
FLT3 PIK3CA
GNA11 PTEN
GNAQ RB1
GNAS RET
HNF1A SMAD4
HRAS VHL
IDH1
IDH2
JAK3
MLH1
MPL
NOTCH1
NRAS
PDGFRA
PTPN11
SMARCB1
SMO
SRC
STK11
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well as in the reference cellular pellet; three synonymous variantsTP53
n the Ion 316 chip V1. The run was set in order to achieve a 1000X
overage for each sample.
Due to the WGA  method, involving an enzymatic cleavage of
NA by the MseI restriction enzyme, we could not sequence 49/207
mplicons of the panel. Table 1 lists the genes of the AmpliSeqTM
ancer Hotspot Panel v2 which are respectively totally, partially or
on-affected by the enzymatic digestion. 31 genes had no amplicon
leaved by the enzyme; 17 genes had some amplicons cut by MseI,
nd two genes (NPM1 and JAK2) were impossible to analyse because
f the enzymatic cleavage.
.7. Data analysis
All samples were processed using the Torrent Suite Software
.6 and variant calling was performed running the Torrent Variant
aller plugin version 3.6.56708. Moreover, samples were analysed
sing NextGENe® software 2.3.1 (SoftGenetics, LLC, State College,
A). We  considered only variants with balanced numbers of for-
ard and reverse reads.
Each variant was investigated about its potential pathogenetic
ole using available gene mutations and SNPs databases and predic-
ion algorithms (COSMIC, dbSNP, 1000GENOME, SIFT, Polyphen).
. Results
.1. Design of the workﬂow for single cell recovery
We  deﬁned a workﬂow for targeted NGS sequencing composed
f the following steps covering the procedure from the blood draw
o the deep sequencing data analysis. Fig. 1 reports the entire
ipeline. and Quantiﬁcation 5 (2015) 23–29 25
3.1.1. Tumor cell enrichment and recovery
The preanalytical variables are taken into account by the use
of a stabilizing blood collection tube which also provides cell ﬁx-
ation. Cells spiked into the blood of a healthy donor are enriched,
ﬂuorescently labelled and counted by the CellSearch® system. The
platform provides the immunomagnetic capture of cells and their
selection on the basis of positive staining for cytokeratins and neg-
ative signal for CD45. The left-over cartridge is handled in order to
achieve the right volume for single cell sorting by the DEPArrayTM,
which combines imaging technologies with the ability to manipu-
late and recover individual cells from a heterogeneous sample. The
system performs a scanning of the sample by an automated ﬂuo-
rescence microscope generating an image gallery. Cells are selected
according to their morphology (round shape, round nucleus within
the cytoplasm) and ﬂuorescence staining pattern deriving from that
of the CellSearch® system. Selected cells are trapped in dielec-
trophoretic “cages” and moved singularly by manipulating the
applied electric ﬁeld [10].
The workﬂow has several critical points related to the complete
CTC recovery from the Cellsearch® cartridge, to the subsequent
volume reduction to ﬁt the input volume of the DEPArrayTM chip
(14 l) and to the volume reduction of single cell samples after
DEPArrayTM recovery.
In particular, after enrichment by the CellSearch® system we
identiﬁed 130 cells (percentage of recovery = 26%). The cell suspen-
sion recovered from the CellSearch® was injected in the DEPArray
chip: we identiﬁed 86 cells with a recovery ratio (deﬁned as
the ratio between the number of single cells identiﬁed by the
DEParrayTM after CellSearch® enrichment and the total number of
cells counted by the CellSearch®) of 66% as already reported in a
previous study [11].
We sorted 5 single MDA-MB-231 cells and a pool of 5 cells to be
submitted to deep sequencing. Fig. 2A shows the images of 2 single
cells.
3.1.2. WGA  and quality control
We  ampliﬁed the whole genome of our samples in a 3-day pro-
cedure required for the Ampli1 WGATM kit. Handling time was
reduced, but two  overnight incubations were required. After the
WGA  reaction we  veriﬁed the quality of the output product before
proceeding to sequencing by a PCR based assay using the Ampli1TM
QC kit. The ﬁve single cells and the pool of 5 cells showed both
the expected PCR products A and B by capillary electrophoresis.
Fig. 2B shows the capillary electrophoresis of the two products of
the Ampli1TM QC kit in two single cells.
3.1.3. Next generation sequencing on single and pooled cells
We successfully sequenced 5 single cells, a pool of 5 cells and
DNA from a pellet of MDA-MB-231 cells with a mean depth of the
sequencing reaction of 2966, 2862, 1581, 1884, 1854, 3479 and
2100 reads respectively.
On the whole 27 sequence variants were detected in 18 genes
(Table 2). Fifteen variants had been already reported in the COSMIC
or dbSNP databases, while 12 were described for the ﬁrst time.
Only two  somatic mutations, p.G464 V in exon 11 of the BRAF
gene and p.R280K in exon 7 of the TP53 gene, had been already
described in this cells line, while the other mutations and sin-
gle nucleotide polymorphisms (SNPs) have never been reported
before.
Two  somatic mutations (p.G464 V in exon 11 of the BRAF gene
and p.R280K in exon 7 of the TP53 gene) and a SNP (p.P72R in exon
3 of the TP53 gene), were detected in single and pooled cells as(p Q787Q in EGFR, p.P567P in PDGFRA and p.L769L in RET) and the
deleterious mutation p.N116Ifs in IDH1 were detected in at least
two samples (single or pooled cells or in the reference pellet), while
26 F. Salvianti et al. / Biomolecular Detection and Quantiﬁcation 5 (2015) 23–29
Fig. 1. Flow chart representing the single steps of the proposed procedure for single cell analysis by NGS.
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B)  Analysis of Ampli1TM QC PCR products for MDA-MB-231 single cell 1 and 2 by c
8 variants were present only in a single cell sample (Table 2). Two
ariants (p.S614I in ATM and p.R927L in ERBB4)  were found only
n the pool (Table 2). All the variants detected in the cellular pellet
ere present in at least one single cell sample (Table 2).
In addition to the identiﬁed variants, Table 2 reports for all sam-
les the number of forward and reverse reads of the mutated base
nd the homozygous or heterozygous status of the variant detected
n each single cell.
Sequence variants common to the 6 samples were detected with
 high number of reads, while a few variants found just in a single
ample had a low number of reads of the mutated nucleotide.
Table 3 reports the mean coverage of each amplicon per sam-
le. In addition, for samples with a detected sequence variant, we
eported the coverage of the speciﬁc position.
. DiscussionWe  described a workﬂow for the molecular characterization
f multiple genes in single cells by NGS. The study represents a
roof-of-principle demonstrating the possibility to investigate the
olecular status of about 50 genes related to cancer developmentescent signals for nuclear DAPI and cytokeratins (PE) and no signal for CD45 (APC).
y electrophoresis. “A = PCR product A; “B” = PCR product B.
in a single tumor cell. The described pipeline can be easily trans-
ferred to the study of single circulating tumor cells from oncologic
patients. In fact, we  demonstrated the feasibility of deep sequenc-
ing on single and pooled pure MDA-MB-231 cells which represent
a model of metastatic breast cancer cells.
One of the purposes of the study was to bypass some of the limi-
tations of the CellSearch®, one of the most widely used systems for
CTC enrichment, in the molecular analysis of patients samples. In
fact, while the instrument was extensively evaluated for its ability
to accurately count CTCs in blood and for the consequent prognos-
tic performances [12–14], it is unable to provide pure samples to
be submitted to molecular characterization: contaminating leuco-
cytes are still present in the enriched samples and the low number
of isolated CTCs substantially limits subsequent molecular analyses
[15,16].
We already demonstrated the possibility to sequence by Sanger
method pure CTC samples enriched by CellSearch® and sorted by
DEPArrayTM [11] and now we would like to extend the procedure
to a higher throughput sequencing system like targeted NGS.
In all our samples we  veriﬁed the presence of two  expected
somatic mutations detectable by the Ion AmpliSeq Cancer Hotspot
F. Salvianti et al. / Biomolecular Detection and Quantiﬁcation 5 (2015) 23–29 27
Table  2
List of the sequence variants detected in single and pooled MDA-MB-231 cells. White boxes represent wild type sequences, while grey boxes indicate the presence of the
mutation. In single cell samples, “homo” and “het” indicate the presence of the mutation in homozygosis or heterozygosis respectively. For all samples, the number of forward
and  reverse reads of the mutated base has been reported for each sequence variant. Sequence variants with possible deleterious effect on the protein phenotype are written
in  bold, while benign variants are reported in plain text. Somatic mutations speciﬁcally investigated by the Ion AmpliSeqTM Cancer Hotspot Panel are highlighted in light
grey.
p
M
o
p
a
aanel on the basis of what is reported for MDA-MB-231 in the COS-
IC  database, demonstrating that NGS fulﬁls the analytical features
f speciﬁcity and accuracy required for single cell analysis.With the exception of the above mentioned mutations and the
.P72R SNP in the TP53 gene, we evidenced a high heterogeneity
mong different cells of the same cancer cell line: nineteen vari-
nts were in fact present in only one of the ﬁve analyzed singlecells. This ﬁnding modiﬁes the idea of cell lines as a pool of isogenic
and homogeneous cells, in fact cells in a culture may  be subjected
to divergent clonal evolution resulting in a heterogeneous mixture
of different genomes. Moreover, all the variants detected in the
cellular pellet were conﬁrmed in at least one single cell indicat-
ing that single cells represent the different clones of the original
population.
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Table 3
List of the sequence variants detected in single and pooled MDA-MB-231 cells with details about the coverage of the next generation sequencing reaction. For single wild
type  cells we reported the mean coverage of the sequenced amplicon; while for mutated single or pooled cells we  reported the mean coverage of the amplicon as well as the
coverage of the speciﬁc mutated nucleotide position. When more than a cell is considered for calculation, the number of cells is reported in brackets.
Gene Sequence variant Single wild type cells Single mutated cells Pool 5 cells
Mean coverage Mean coverage Single base coverage Mean coverage Single base coverage
ABL1 p.M337IM 9965 (n = 4) 5493 4718 8377
APC  p.P1458A 7483 (n = 4) 5721 4784 11545
ATM  p.S614I 336 (n = 5) 1101 985
ATM  p.T616A 372 (n = 4) 191 176 1101
BRAF  p.G464V 1937 (n = 5) 1712 (n = 5) 4363 3688
BRAF  p.S607P 549 (n = 4) 808 739
EGFR p.Q787Q 6050 (n = 2) 1664 (n = 3) 1423 (n = 3)
ERBB4 p.R927L 558 (n = 5) 1356 1200
ERBB4  p.P942H 538 (n = 4) 640 559 1356
FBXW7 p.H495N 2788 (n = 4) 600 545 4475
FLT3  p.E588Vfs 1932 (n = 4) 1095 975 3502
IDH1  p.C114F 9337 (n = 4) 4856 3306 15573
IDH1  p.N116Ifs 8012 (n = 4) 10155 9003 15573
KIT  p.L526M 1227 (n = 4) 929 818 2405
KRAS  p.R135G 597 (n = 4) 416 350 1980
MLH1  p.E414E 7435 (n = 4) 4831 4222 14523
PDGFRA p.P567P 2586 (n = 2) 3513 (n = 3) 2973(n  = 3) 3933
PTEN  p.K6K 3823 (n = 4) 3066 2837 7575
PTEN  p.D19Y 3562 (n = 4) 4109 3380 7575
RET  p.L769L 52 (n = 4) 167 150 45
SMARCB1 p.A55DA 9550 (n = 4) 6130 5279 10136
SMARCB1 p.R201Efs 7089 (n = 4) 4686 4055 6902
SMO  p.T640A 3114 (n = 4) 9737 8450 4748
TP53  p.P72R 3321 (n = 5) 2668 (n = 5) 1989 1514
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mTP53  p.S166L 14711 (n = 4) 6567 
TP53  p.R280K 2886 (n = 5
TP53  p.G356W 3243 (n = 4) 3998 
Previous studies showed that ampliﬁcation and sequencing
rrors are a concern for single cell mutation analysis [17], but the
unctual and mean high coverage reached for our samples make
s conﬁdent on the reliability of even minor variants found only in
ingle samples. In fact achieving high physical coverage of the tar-
eted sequences is crucial for calling mutations at the same regions
cross multiple single cells Navine, [3].
As a matter of fact, we cannot exclude technical errors deriving
rom the WGA  procedure. As already pointed out by other authors,
GA  could affect subsequent sequencing results by introducing a
umber of technical variables such as allelic dropout, inadequate
overage, false positive and negative results [3]. For this reason we
hose to adopt a WGA  method which has been shown to reliably
mplify the entire cellular genome homogeneously [18].
It is generally accepted that, due to high error rates in NGS, muta-
ions must be detected in multiple single cells (at least 3 cells) to
ake a mutant call [3]. Nonetheless with the aim to report the
ntire results of the proposed workﬂow and to highlight cell het-
rogeneity, we decided to report all the variants detected in each
ingle cell provided that the number of forward and reverse reads
or the mutated base was balanced.
The feasibility of high-resolution single cell analysis is very
mportant when applied to the study of CTCs which are extremely
are in the bloodstream and, due to the challenge in the devel-
pment of isolation procedures, can be often recovered in low
umbers from a single blood draw.
Single cell analysis may  assume even higher relevance when
ealing with samples from cancer patients in whom such methods
ould help elucidating tumor heterogeneity in a variety of speci-
ens, such as primary tissues, metastases and circulating tumor
ells. CTCs in particular are rare in the circulation and require
ighly sensitive and speciﬁc methods for their isolation and high
hroughput procedures for nucleic acid characterization in order to
ighlight their metastatic potential and their usefulness as dynamic
arkers of tumor development.5564 17535
2508 (n = 5) 5417 4670
3408 2897
Our study is an example of optimization of single-cell analy-
sis procedures which are still in development and hold promise
to establish robust single-cell diagnostics which will be crucial for
the realization of precision medicine implying novel therapeutic
approaches [6].
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